应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
已收盘 04-25 16:09:09
0.940
-0.010
-1.05%
最高
0.960
最低
0.920
成交量
51.80万
今开
0.940
昨收
0.950
日振幅
4.21%
总市值
4.21亿
流通市值
4.21亿
总股本
4.47亿
成交额
48.53万
换手率
0.12%
流通股本
4.47亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域
证券之星 · 59分钟前
拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域
万润股份:公司生命科学与医药产品销售种类较多,不同产品售价不同,各报告期订单结构也存在不同
证券之星 · 18:02
万润股份:公司生命科学与医药产品销售种类较多,不同产品售价不同,各报告期订单结构也存在不同
4月25日常山药业涨停分析:化学原料药,创新药,医药概念热股
证券之星 · 15:28
4月25日常山药业涨停分析:化学原料药,创新药,医药概念热股
港股概念追踪 |2024年医药流通企业并购整合趋势有望进一步加速 龙头国企受关注(附概念股)
智通财经 · 13:46
港股概念追踪 |2024年医药流通企业并购整合趋势有望进一步加速 龙头国企受关注(附概念股)
【兴证医药】2024ASCO会议国产创新药品种梳理
兴证医药健康 · 11:46
【兴证医药】2024ASCO会议国产创新药品种梳理
国投证券:行业国资密集 24年医药流通企业并购整合趋势有望进一步加速
智通财经 · 11:22
国投证券:行业国资密集 24年医药流通企业并购整合趋势有望进一步加速
亚盛医药-B(06855.HK):四项研究入选ASCO年会,耐立克?治疗SDH缺陷型GIST 最新进
智通财经 · 10:47
亚盛医药-B(06855.HK):四项研究入选ASCO年会,耐立克?治疗SDH缺陷型GIST 最新进
A股开盘速递 | 医药板块反弹 业绩超预期股大涨
智通财经网 · 09:48
A股开盘速递 | 医药板块反弹 业绩超预期股大涨
【港股通】亚盛医药-B(06855)四项临床研究入选ASCO年会 耐立克®获口头报告
金吾财讯 · 09:03
【港股通】亚盛医药-B(06855)四项临床研究入选ASCO年会 耐立克®获口头报告
亚盛医药-B(06855.HK)四项临床研究入选美国临床肿瘤学会年会
阿斯达克财经 · 08:12
亚盛医药-B(06855.HK)四项临床研究入选美国临床肿瘤学会年会
华泰 | 医药:胰岛素续约降幅温和,国产替代加速
华泰睿思 · 07:41
华泰 | 医药:胰岛素续约降幅温和,国产替代加速
亚盛医药-B(06855):四项研究入选ASCO年会,耐立克®治疗SDH缺陷型GIST 最新进展获口头报告
智通财经 · 07:02
亚盛医药-B(06855):四项研究入选ASCO年会,耐立克®治疗SDH缺陷型GIST 最新进展获口头报告
国君医药|胰岛素集采结果出炉,国产替代有望提速
国泰君安证券研究 · 07:00
国君医药|胰岛素集采结果出炉,国产替代有望提速
万春医药上涨3.96%,报2.38美元/股
金融界 · 04-24 22:00
万春医药上涨3.96%,报2.38美元/股
诺思格:2024年1月公司收购上海衡领医药科技有限公司
证券之星 · 04-24 20:01
诺思格:2024年1月公司收购上海衡领医药科技有限公司
海王生物最新公告:子公司拟投建海王智慧医药物流园
证券之星 · 04-24 19:30
海王生物最新公告:子公司拟投建海王智慧医药物流园
花园生物:公司维生素D3包括饲料级维生素D3及食品医药级维生素D3
证券之星 · 04-24 18:04
花园生物:公司维生素D3包括饲料级维生素D3及食品医药级维生素D3
押宝脱发治疗市场,开拓药业胜算几何?
新京报网 · 04-24 11:33
押宝脱发治疗市场,开拓药业胜算几何?
观点集锦 · 医药专场|国君研究2024春季策略会
国泰君安证券研究 · 04-24 07:00
观点集锦 · 医药专场|国君研究2024春季策略会
天士力2023年扭亏:净利润同比增长超五倍 医药商业收入下滑
中国网财经 · 04-23 19:14
天士力2023年扭亏:净利润同比增长超五倍 医药商业收入下滑
加载更多
公司概况
公司名称:
开拓药业-B
所属市场:
SEHK
上市日期:
--
主营业务:
开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。
发行价格:
--
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":0.94,"timestamp":1714032549019,"preClose":0.95,"halted":0,"volume":518000,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-2.664085,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.01,"latestTime":"04-25 16:09:09","open":0.94,"high":0.96,"low":0.92,"amount":485275,"amplitude":0.042105,"askPrice":0.95,"askSize":10000,"bidPrice":0.94,"bidSize":50500,"shortable":0,"etf":0,"ttmEps":-2.6640848169719744,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714095000000},"adr":0,"listingDate":1590076800000,"adjPreClose":0.95,"openAndCloseTimeList":[[1714008600000,1714017600000],[1714021200000,1714032000000]],"volumeRatio":0.209369,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939/","defaultTab":"news","newsList":[{"id":"2430140653","title":"拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2430140653","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430140653?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:02","pubTimestamp":1714042932,"startTime":"0","endTime":"0","summary":"拓新药业董秘:公司研发成果请您关注公司披露的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500039625.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430725974","title":"万润股份:公司生命科学与医药产品销售种类较多,不同产品售价不同,各报告期订单结构也存在不同","url":"https://stock-news.laohu8.com/highlight/detail?id=2430725974","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430725974?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:02","pubTimestamp":1714039351,"startTime":"0","endTime":"0","summary":"公司一向依法合规经营,公司的财务报表和财务报告严格按照《企业会计准则》规定编制,能够公允的反映公司的财务状况、经营成果和现金流量。谢谢万润股份董秘:您好,公司根据实际经营情况进行存货管理,公司2024年一季度末存货较2023年末的存货减少,后续存货情况请见公司的定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500038742.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430421337","title":"4月25日常山药业涨停分析:化学原料药,创新药,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430421337","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430421337?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:28","pubTimestamp":1714030125,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业涨停收盘,收盘价11.77元。该股于9点31分涨停,未打开涨停,截止收盘封单资金为1.57亿元,占其流通市值1.45%。4月25日的资金流向数据方面,主力资金净流入2.19亿元,占总成交额41.29%,游资资金净流出1.31亿元,占总成交额24.68%,散户资金净流出8800.39万元,占总成交额16.61%。近5日资金流向一览见下表:该股为化学原料药,创新药,医药概念热股,当日化学原料药概念上涨2.05%,创新药概念上涨1.85%,医药概念上涨1.42%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500026171.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430440384","title":"港股概念追踪 |2024年医药流通企业并购整合趋势有望进一步加速 龙头国企受关注(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2430440384","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430440384?lang=zh_cn&edition=full","pubTime":"2024-04-25 13:46","pubTimestamp":1714024003,"startTime":"0","endTime":"0","summary":"据新京报,近日,北京市卫健委、市中医药管理局联合发布《北京市“优质服务基层行”活动和社区医院建设三年行动方案》,加强北京市基层医疗卫生机构服务能力建设。到2025年,实现人财物乡村一体化管理的村卫生室比例力争达到60%以上。值得注意的是,新一轮国企改革亦强调医药健康领域的专业化整合,医药流通行业国资密集,叠加政策驱动下,在2024年这一时间点,国内医药流通企业并购整合趋势有望进一步加速,龙头集中度或将进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109584.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430441921","title":"【兴证医药】2024ASCO会议国产创新药品种梳理","url":"https://stock-news.laohu8.com/highlight/detail?id=2430441921","media":"兴证医药健康","top":-1,"share":"https://www.laohu8.com/m/news/2430441921?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:46","pubTimestamp":1714016760,"startTime":"0","endTime":"0","summary":"在任何情况下,作者及作者所在团队、兴业证券股份有限公司不对任何人因使用本平台中的任何内容所引致的任何损失负任何责任。本平台旨在沟通研究信息,交流研究经验,不是兴业证券股份有限公司研究报告的发布平台,所发布观点不代表兴业证券股份有限公司观点。任何完整的研究观点应以兴业证券股份有限公司正式发布的报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA4NjAxNzEzNw==&mid=2650184762&idx=1&sn=f89f30ba7455571df18cb4e5bc143a30&chksm=86fc0db66d00eb1ce1d29c08a3f933d69da5e42befc0ac5e4517882a7f812187cb34ce92a31b&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430445133","title":"国投证券:行业国资密集 24年医药流通企业并购整合趋势有望进一步加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2430445133","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430445133?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:22","pubTimestamp":1714015370,"startTime":"0","endTime":"0","summary":"值得注意的是,新一轮国企改革亦强调医药健康领域的专业化整合,医药流通行业国资密集,叠加政策驱动下,在2024年这一时间点,国内医药流通企业并购整合趋势有望进一步加速,龙头集中度或将进一步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109557.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430445348","title":"亚盛医药-B(06855.HK):四项研究入选ASCO年会,耐立克?治疗SDH缺陷型GIST 最新进","url":"https://stock-news.laohu8.com/highlight/detail?id=2430445348","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430445348?lang=zh_cn&edition=full","pubTime":"2024-04-25 10:47","pubTimestamp":1714013242,"startTime":"0","endTime":"0","summary":"亚盛医药-B (06855.HK)发布公告,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会(ASCO)年会,其中一项获口头报告。这三个重点品种分别为中国首个且唯一获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(HQP1351;商品名:耐立克?)、Bcl-2选择性抑制剂APG-2575、和FAK/ALK/ ROS1三联抑制剂APG-2449。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511303287ad5026&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511303287ad5026&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430946412","title":"A股开盘速递 | 医药板块反弹 业绩超预期股大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2430946412","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430946412?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:48","pubTimestamp":1714009737,"startTime":"0","endTime":"0","summary":"4月25日,A股早盘震荡走弱,盘面上,医药股集体反弹,减肥药板块领涨。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240425/20240425095203_63903.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240425/20240425095203_63903.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109508.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430419821","title":"【港股通】亚盛医药-B(06855)四项临床研究入选ASCO年会 耐立克®获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2430419821","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2430419821?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:03","pubTimestamp":1714006995,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药-B(06855)宣布,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会(ASCO)年会,其中耐立克®获口头报告。这三个重点品种分别为中国首个且唯一获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(HQP1351;商品名:耐立克®)、Bcl-2选择性抑制剂APG-2575、和FAK/ALK/ROS1三联抑制剂APG-2449。","market":"us","thumbnail":"https://static.szfiu.com/news/20210510/ZGJjYTkxOGYyMGNlOTUwNjQ0NzUyMDkw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210510/ZGJjYTkxOGYyMGNlOTUwNjQ0NzUyMDkw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935736","is_publish_highlight":false,"gpt_icon":0},{"id":"2430415439","title":"亚盛医药-B(06855.HK)四项临床研究入选美国临床肿瘤学会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2430415439","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430415439?lang=zh_cn&edition=full","pubTime":"2024-04-25 08:12","pubTimestamp":1714003920,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855.HK) 公布,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会(ASCO)年会,其中一项获口头报告。该三个重点品种分别为中国首个且唯一获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(HQP1351;商品名:耐立克)、Bcl-2选择性抑制剂APG-2575、和FAK/ALK/ROS1三联抑制剂APG-2449。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-24 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201214152342289_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201214152342289_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344840/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430141984","title":"华泰 | 医药:胰岛素续约降幅温和,国产替代加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2430141984","media":"华泰睿思","top":-1,"share":"https://www.laohu8.com/m/news/2430141984?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:41","pubTimestamp":1714002060,"startTime":"0","endTime":"0","summary":"核心观点价:价格策略分化,整体保留合理利润空间本次胰岛素集采价格整体降幅约3.8%,其中二代平均降幅约2.4%,三代平均降幅约5.2%。量:格局变化不大,龙头国产替代加速本次集采共报量2.4亿支,且A类中标厂商较多,集采前后整体格局变化不大,但国产厂家份额有所提升,龙头国产替代加速进行,国产小厂家份额变化不大,进口份额下降。如因侵权行为给华泰证券造成任何直接或间接的损失,华泰证券保留追究一切法律责任的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649760402&idx=3&sn=146cc6034103993a7d8ef51cf9400d60&chksm=89c7be69534dc170d43e4afc515ea21f2b96741a5bd501b68c45300e1c47d9bb555b6921f7f8&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430908364","title":"亚盛医药-B(06855):四项研究入选ASCO年会,耐立克®治疗SDH缺陷型GIST 最新进展获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2430908364","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430908364?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:02","pubTimestamp":1713999730,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亚盛医药-B 发布公告,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会年会,其中一项获口头报告。一年一度的ASCO年会是全球肿瘤领域最重要、最权威的学术交流盛会,将展示当前国际最前沿的临床肿瘤学科研成果和肿瘤治疗技术。本届ASCO年会将于2024年5月31日2024年至6月4日在美国伊利诺伊州芝加哥 McCormick会议中心以线上线下结合的形式举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109452.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430416650","title":"国君医药|胰岛素集采结果出炉,国产替代有望提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2430416650","media":"国泰君安证券研究","top":-1,"share":"https://www.laohu8.com/m/news/2430416650?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:00","pubTimestamp":1713999600,"startTime":"0","endTime":"0","summary":"事件:2024年4月23日,国家组织药品联合采购办公室发布公告,公示胰岛素专项接续采购拟中选结果。本批集采预计于5月开始在全国落地实施,与上一轮胰岛素集采平稳有序衔接。与之同时,国产胰岛素报价积极,甘李药业4款产品中选A类、通化东宝6款产品中选A类、联邦制药6款产品中选A类,预计国产胰岛素将迎来进口替代的持续提速。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650479374&idx=4&sn=a4ac1d9e8dfaa23c733b0c7de07ecb2c&chksm=89c459b821527cda39f36ca761d6e1b57cbd839aff97146c853a0c88365fe80dafd9d5ee4638&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2429514634","title":"万春医药上涨3.96%,报2.38美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429514634","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429514634?lang=zh_cn&edition=full","pubTime":"2024-04-24 22:00","pubTimestamp":1713967233,"startTime":"0","endTime":"0","summary":"4月24日,万春医药(BYSI)盘中上涨3.96%,截至22:00,报2.38美元/股,成交5995.0美元。财务数据显示,截至2023年06月30日,万春医药收入总额87.5万美元,同比增长29.44%;归母净利润-1272.0万美元,同比增长31.2%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/24220040393487.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429643799","title":"诺思格:2024年1月公司收购上海衡领医药科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2429643799","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429643799?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:01","pubTimestamp":1713960060,"startTime":"0","endTime":"0","summary":"2024年1月公司收购上海衡领医药科技有限公司。上海衡领医药科技有限公司于2019年10月成立,专注于创新药物体内外药物代谢动力学评价服务。另外,公司2023年限制性股票激励计划将于2024年第一至三季度每季度分别摊销1,303.50万元,第四季度摊销639.86万元,全年合计摊销4,550.36万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400042236.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429349004","title":"海王生物最新公告:子公司拟投建海王智慧医药物流园","url":"https://stock-news.laohu8.com/highlight/detail?id=2429349004","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429349004?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:30","pubTimestamp":1713958250,"startTime":"0","endTime":"0","summary":"海王生物公告,为满足公司未来经营发展的需要,公司全资子公司山东银河拟与潍坊高新技术产业开发区管理委员会签署《海王智慧医药物流园项目合同书》,以招拍挂方式取得新地块(具体价格以实际成交价格为准),计划首期投资2.98亿元建设公司智能化医药物流中心。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400040641.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429443815","title":"花园生物:公司维生素D3包括饲料级维生素D3及食品医药级维生素D3","url":"https://stock-news.laohu8.com/highlight/detail?id=2429443815","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429443815?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:04","pubTimestamp":1713953063,"startTime":"0","endTime":"0","summary":"公司维生素D3包括饲料级维生素D3及食品医药级维生素D3。维生素D3作为饲料添加剂,主要供食用动物做补钙用。目前多巴丝肼片正在生产中。公司目前已与国内主要饲料生产厂商建立了良好的合作关系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400038079.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429170520","title":"押宝脱发治疗市场,开拓药业胜算几何?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429170520","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2429170520?lang=zh_cn&edition=full","pubTime":"2024-04-24 11:33","pubTimestamp":1713929580,"startTime":"0","endTime":"0","summary":"千亿元的脱发治疗市场,依然有许多未满足需求,押宝脱发治疗市场的开拓药业,胜算几何?消息公布后,开拓药业股价下跌,当日下挫31.86%。2023年11月27日至今年4月23日收盘,开拓药业股价已累计下跌71.68%。单药临床研究疗效未达预期,开拓药业又瞄准了联合疗法的开发。如今,随着新冠疫情相对缓和,加上新冠肺炎口服小分子药物市场竞争激烈,开拓药业自愿暂停了普克鲁胺在新冠肺炎适应症的临床支出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404241135127922d7b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404241135127922d7b0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429105998","title":"观点集锦 · 医药专场|国君研究2024春季策略会","url":"https://stock-news.laohu8.com/highlight/detail?id=2429105998","media":"国泰君安证券研究","top":-1,"share":"https://www.laohu8.com/m/news/2429105998?lang=zh_cn&edition=full","pubTime":"2024-04-24 07:00","pubTimestamp":1713913200,"startTime":"0","endTime":"0","summary":"4月23日,国泰君安2024年上市公司见面会暨春季策略会——医药“成长新动能,创新与国际化齐驱”论坛于上海举行。公立医院超1万亿药品销售额中,近一半在门急诊,潜在外流空间巨大。截至2023年8月,定点药店已有29%接入统筹,可有效提升门店增速。考虑实体药店高度密集,O2O渗透率提升幅度预计有限,龙头凭借供应链优势可获得更高O2O市场份额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650479330&idx=1&sn=91278e171fedc298390c020149036541&chksm=89f71581a4a10784c66c7dfa236a23aade8fa3c4e88cb2541c633da5021a77f7e867bf5357be&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2429024111","title":"天士力2023年扭亏:净利润同比增长超五倍 医药商业收入下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2429024111","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2429024111?lang=zh_cn&edition=full","pubTime":"2024-04-23 19:14","pubTimestamp":1713870888,"startTime":"0","endTime":"0","summary":"中国网财经4月23日讯 天士力近日披露2023年年报。2023年,天士力实现营业收入86.74亿元,同比增长0.42%;归母净利润10.71亿元,同比增长505.34%;扣非净利润11.81亿元,同比增长60.11%,拟向全体股东每10股派3.3元(含税)。 对于扭亏的原因,天士力表示,主要系报告期内金融资产公允价值变动损失低于上年所致。天士力期内...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/O0kbJCe0GNsbm1wptWm4Fu0s8dqt1HnTcVx4MOFl9gD-kAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/O0kbJCe0GNsbm1wptWm4Fu0s8dqt1HnTcVx4MOFl9gD-kAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240423A08K7Q00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240423A08K7Q00","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.1585},{"period":"1month","weight":0.0326},{"period":"3month","weight":-0.2803},{"period":"6month","weight":-0.6533},{"period":"1year","weight":-0.8234},{"period":"ytd","weight":-0.4172}],"compareEarnings":[{"period":"1week","weight":0.0584},{"period":"1month","weight":0.0442},{"period":"3month","weight":0.061},{"period":"6month","weight":-0.0113},{"period":"1year","weight":-0.1232},{"period":"ytd","weight":0.009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.058646},{"month":2,"riseRate":0.75,"avgChangeRate":0.213088},{"month":3,"riseRate":0.25,"avgChangeRate":0.062774},{"month":4,"riseRate":0.75,"avgChangeRate":0.551443},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.091618},{"month":6,"riseRate":0.25,"avgChangeRate":-0.077338},{"month":7,"riseRate":0.75,"avgChangeRate":0.030119},{"month":8,"riseRate":0.25,"avgChangeRate":-0.047081},{"month":9,"riseRate":0,"avgChangeRate":-0.284122},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084422},{"month":11,"riseRate":0.75,"avgChangeRate":0.089012},{"month":12,"riseRate":0.25,"avgChangeRate":-0.241375}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}